Whole Exome Sequencing (WES) and Minimal Residual Disease (MRD) are techniques allowing matching of the genetic sequences detected in your tumor biopsy to 20,000 known genes from our database
Minimal Residual Disease refers to the small number of residual cancer cells circulating in the blood after cancer treatment. Detection of any remaining circulating cancer cells means there is MRD, or ongoing untreated cancer. Our MRD testing accurately detects any remaining cancer cells, indicating successful treatment if all cancer cells disappear from the circulation
The same technology used for MRD can also be used to detect tumor recurrence and for ongoing monitoring of patients who have been successfully treated
Our proprietary technologies include OriCleverClover, which is a highly sensitive test with a low false positive rate. OriSelector precisely selects monitoring sites
Testing Portfolio | Detection Technology | Specimen Type | Cancer Type |
---|---|---|---|
MiYuan OriMIRACLE LTM | BCR/TC rearrangement | Bone marrow fluid 、Peripheral blood、FFPE sample | Lymphatic hematologic tumor |
OriMIRACLE STM | WES+MRD | Tumor tissue +ctDNA | All solid tumors |
700+gene solid tumor
40+— 20000+solid tumor
FDA-approved immunization checkpoint IHC testing
5th Floor, Building 3, 115 Xinjun Ring Road, Minhang District, Shanghai
Floor 4, Information Building 2, Zhaolou Road 3576 , Pujiang Town, Minhang District, Shanghai
400-821-9890
Service Hours:9:00-18:00 Monday to Friday (except statutory holidays)
zbservice@origimed.com
We will reply you as soon as we receive the email.
All rights reserved in © Copyright 2022 OrigiMed Ltd
Registration Number:沪ICP备16027109号-1